Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed leukemia or lymphoma refractory to standard curative treatment regimens~* Measurable or evaluable disease~* No meningeal leukemia or lymphoma~* No HIV-related lymphoma~* No lymphoproliferative diseases~PATIENT CHARACTERISTICS:~Age:~* 2 to 21~  * Acute promyelocytic leukemia (APL) patients (stratum I) must be age 2 to 12~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin normal~* SGPT less than 2 times upper limit of normal~* No significant hepatic dysfunction that would preclude study therapy~Renal:~* Creatinine normal (age adjusted) OR~* Creatinine clearance at least 60 mL/min~* Potassium, magnesium, and calcium at least lower limit of normal (oral or IV supplementation allowed)~* No significant renal dysfunction that would preclude study therapy~Cardiovascular:~* Rate corrected QTc interval no greater than 0.48 on EKG~* No significant cardiac dysfunction that would preclude study therapy~* No cardiac disease, including dysrhythmias~Pulmonary:~* No significant pulmonary dysfunction that would preclude study therapy~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No persistent grade 3 or greater sensory or motor neuropathy~* No prior grand mal seizures (grade 3 or greater) within the past 2 years other than febrile seizures (except for patients with APL at discretion of investigator)~* No clinically significant unrelated systemic illness that would preclude study therapy (e.g., serious infection)~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 1 week since prior colony-stimulating factors (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], and epoetin alfa)~* No concurrent immunotherapy~Chemotherapy:~* No prior arsenic trioxide~* At least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas) and recovered~* No concurrent intrathecal chemotherapy except for acute promyelocytic leukemia (APL) patients experiencing progressive meningeal leukemia and demonstrating benefit from arsenic trioxide for systemic disease~* No other concurrent anticancer chemotherapy~Endocrine therapy:~* No concurrent steroids (except corticosteroids for retinoic acid syndrome)~Radiotherapy:~* At least 4 weeks since prior radiotherapy and recovered~* No concurrent radiotherapy~Surgery:~* Not specified~Other:~* At least 6 months since prior anticonvulsants~* At least 1 week since prior retinoid therapy~* No concurrent retinoids~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete